NASDAQ:PULM Pulmatrix (PULM) Stock Price, News & Analysis $2.11 -0.01 (-0.47%) (As of 10/14/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Pulmatrix Stock (NASDAQ:PULM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pulmatrix alerts:Sign Up Key Stats Today's Range$2.02▼$2.1250-Day Range$1.79▼$2.4052-Week Range$1.55▼$2.75Volume1,992 shsAverage Volume13,587 shsMarket Capitalization$7.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.Read More… The most serious warning of my career (Ad)With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. Click here now to grab your seat now. Pulmatrix Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks30th Percentile Overall ScorePULM MarketRank™: Pulmatrix scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pulmatrix.Read more about Pulmatrix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmatrix is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmatrix is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmatrix has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pulmatrix's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.14% of the float of Pulmatrix has been sold short.Short Interest Ratio / Days to CoverPulmatrix has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulmatrix has recently decreased by 20.31%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPulmatrix does not currently pay a dividend.Dividend GrowthPulmatrix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.14% of the float of Pulmatrix has been sold short.Short Interest Ratio / Days to CoverPulmatrix has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulmatrix has recently decreased by 20.31%, indicating that investor sentiment is improving significantly. News and Social Media3.9 / 5News Sentiment0.95 News SentimentPulmatrix has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Pulmatrix this week, compared to 0 articles on an average week.Search Interest1 people have searched for PULM on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Pulmatrix to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pulmatrix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.61% of the stock of Pulmatrix is held by insiders.Percentage Held by InstitutionsOnly 11.84% of the stock of Pulmatrix is held by institutions.Read more about Pulmatrix's insider trading history. Receive PULM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter. Email Address PULM Stock News HeadlinesPulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.comOctober 10, 2024 | americanbankingnews.comPulmatrix (NASDAQ:PULM) Files 8-K - Acquisition of iMD TherapeuticsOctober 9, 2024 | americanbankingnews.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 14, 2024 | Porter & Company (Ad)Pulmatrix Second Quarter 2024 Earnings: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023)August 15, 2024 | finance.yahoo.comPulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | prnewswire.comPulmatrix IncJuly 30, 2024 | money.usnews.comMNKD Jul 2024 6.000 call (MNKD240726C00006000)July 20, 2024 | finance.yahoo.comMNKD Jul 2024 5.000 put (MNKD240726P00005000)July 20, 2024 | finance.yahoo.comSee More Headlines PULM Stock Analysis - Frequently Asked Questions How have PULM shares performed this year? Pulmatrix's stock was trading at $1.86 at the beginning of 2024. Since then, PULM shares have increased by 13.4% and is now trading at $2.11. View the best growth stocks for 2024 here. How were Pulmatrix's earnings last quarter? Pulmatrix, Inc. (NASDAQ:PULM) posted its earnings results on Tuesday, August, 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $1.55 million for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative trailing twelve-month return on equity of 46.86%. When did Pulmatrix's stock split? Shares of Pulmatrix reverse split before market open on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Pulmatrix? Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Pulmatrix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmatrix investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), General Electric (GE), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO) and Adobe (ADBE). Company Calendar Last Earnings8/13/2024Today10/14/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PULM CUSIPN/A CIK1574235 Webwww.pulmatrix.com Phone(781) 357-2333Fax707-525-9906Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,120,000.00 Net Margins-95.18% Pretax Margin-95.18% Return on Equity-46.86% Return on Assets-28.14% Debt Debt-to-Equity RatioN/A Current Ratio6.33 Quick Ratio6.33 Sales & Book Value Annual Sales$7.30 million Price / Sales1.06 Cash FlowN/A Price / Cash FlowN/A Book Value$4.93 per share Price / Book0.43Miscellaneous Outstanding Shares3,650,000Free Float3,520,000Market Cap$7.74 million OptionableNot Optionable Beta1.00 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:PULM) was last updated on 10/14/2024 by MarketBeat.com Staff From Our PartnersThe Masterworks of Cars - MCQ MarketsMCQ Markets is launching a new innovative platform that allows car enthusiasts to be able to invest in fractio...Issuance Express | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe Standard Oil of AI?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredHave you heard of Donald Trump’s Project Crypto?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredUnlock This Opportunity Before October 22nd: Discover Elon Musk's Latest AI Device!This is Elon Musk's latest AI innovation… According to Eric Fry, a seasoned expert with 30 years of experie...InvestorPlace | SponsoredFREE investing Class TOMORROW + 2 FREE BonusesOver the last 37 years on Wall Street, I've developed a unique investing strategy that allows me to find stock...Unstoppable Prosperity | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmatrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.